Pim kinases in hematological malignancies: where are we now and where are we going?

Journal of Hematology & Oncology

Michael Mian²  Salvatore Cuzzocrea¹  Patrizia Mondello¹ 

[1] Department of Biological and Environmental Sciences, University of Messina, Messina, Italy;Department of Internal Medicine V, Hematology & Oncology, Medical University Innsbruck, Innsbruck, Austria

关键词: Pim inhibitors;    Hematologic malignancies;    Target therapy;    Pim kinases;   

Others  :  1137549
DOI  :  10.1186/s13045-014-0095-z

 received in 2014-09-22, accepted in 2014-12-04,  发布年份 2014

【 摘 要 】

The proviral insertion in murine (PIM) lymphoma proteins are a serine/threonine kinase family composed of three isoformes: Pim-1, Pim-2 and Pim-3. They play a critical role in the control of cell proliferation, survival, homing and migration. Recently, overexpression of Pim kinases has been reported in human tumors, mainly in hematologic malignancies. In vitro and in vivo studies have confirmed their oncogenic potential. Indeed, PIM kinases have shown to be involved in tumorgenesis, to enhance tumor growth and to induce chemo-resistance, which is why they have become an attractive therapeutic target for cancer therapy. Novel molecules inhibiting Pim kinases have been evaluated in preclinical studies, demonstrating to be effective and with a favorable toxicity profile. Given the promising results, some of these compounds are currently under investigation in clinical trials. Herein, we provide an overview of the biological activity of PIM-kinases, their role in hematologic malignancies and future therapeutic opportunities.

【 授权许可】

   
2014 Mondello et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Nawijn MC, Alendar A, Berns A: For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011, 11:23-34.
• [2]Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB: The serine/threonine kinase Pim- 2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003, 17:1841-1854.
• [3]Qian KC, Wang L, Hickey ER, Studts J, Barringer K, Peng C, Kronkaitis A, Li J, White A, Mische S, Farmer B: Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 2005, 280:6130-6137.
• [4]Allen JD, Verhoeven E, Domen J, van der Valk M, Berns A: Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 1997, 15:1133-1141.
• [5]Dautry F, Weil D, Yu J, Dautry-Varsat A: Regulation of pim and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines. J Biol Chem 1988, 263:17615-17620.
• [6]Lilly M, Le T, Holland P, Hendrickson SL: Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. Oncogene 1992, 7:727-732.
• [7]Pratt WB: The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Annu Rev Pharmacol Toxicol 1997, 37:297-326.
• [8]Mizuno K, Shirogane T, Shinohara A, Iwamatsu A, Hibi M, Hirano T: Regulation of Pim-1 by Hsp90. Biochem Biophys Res Commun 2001, 281:663-669.
• [9]Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA, Skorski T: Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood 2002, 99:4531-4539.
• [10]Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M: The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 2008, 111:3751-3759.
• [11]Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, Small D: Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 2005, 105:1759-1767.
• [12]Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J, Berns A: Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004, 24:6104-6115.
• [13]Eichmann A, Yuan L, Bréant C, Alitalo K, Koskinen PJ: Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Oncogene 2000, 19:1215-1224.
• [14]Bachmann M, Möröy T: The serine/threoninekinasePim-1. Int J Biochem Cell Biol 2005, 37:726-730.
• [15]Feldman JD, Vician L, Crispino M, Tocco G, Marcheselli VL, Bazan NG, Baudry M, Herschman HR: KID-1, a protein kinase induced by depolarization in brain. J Biol Chem 1998, 273:16535-16543.
• [16]Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
• [17]Cohen AM, Grinblat B, Bessler H, Kristt D, Kremer A, Schwartz A, Halperin M, Shalom S, Merkel D, Don J: Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2004, 45:951-955.
• [18]Wingett D, Long A, Kelleher D, Magnuson NS: Pim-1 proto-oncogene expression in anti-CD3- mediated T-cell activation is associated with pro- tein kinase C activation and is independent of Raf-1. J Immunol 1996, 156:549-557.
• [19]Cibull TL, Jones TD, Li L, Eble JN, Ann Baldridge L, Malott SR, Luo Y, Cheng L: Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol 2006, 59:285-288.
• [20]Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, Lilly MB, Salto-Tellez M: Potential roles for the PIM1 kinase in human cancer - a molecular and therapeuticappraisal. Eur J Cancer 2008, 44:2144-2151.
• [21]Van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, Berns A: Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989, 56:673-682.
• [22]van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A: Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991, 65:737-752.
• [23]Berns A: Tumorigenesis in transgenic mice: identification and characterization of synergizing oncogenes. J Cell Biochem 1991, 47:130-135.
• [24]Verbeek S, van Lohuizen M, van der Valk M, Domen J, Kraal G, Berns A: Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol Cell Biol 1991, 11:1176-1179.
• [25]Kim J, Roh M, Abdulkadir SA: Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer 2010, 10:248.
• [26]Shinto Y, Morimoto M, Katsumata M, Uchida A, Aozasa K, Okamoto M, Kurosawa T, Ochi T, Greene MI, Tsujimoto Y: Moloney murine leukemia virus infection accelerates lymphomagenesis in E mu-bcl-2 transgenic mice. Oncogene 1995, 11:1729-1736.
• [27]Baron BW, Anastasi J, Hyjek EM, Bies J, Reddy PL, Dong J, Joseph L, Thirman MJ, Wroblewski K, Wolff L, Baron JM: PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas. Proc Natl Acad Sci U S A 2012, 109:5735-5739.
• [28]Blyth K, Terry A, Mackay N, Vaillant F, Bell M, Cameron ER, Neil JC, Stewart M: Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 2001, 20:295-302.
• [29]Feldman BJ, Reid TR, Cleary ML: Pim1 cooperates with E2a-Pbx1 to facilitate the progression of thymic lymphomas in transgenic mice. Oncogene 1997, 15:2735-2742.
• [30]Jonkers J, Korswagen HC, Acton D, Breuer M, Berns A: Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas. EMBO J 1997, 16:441-450.
• [31]An N, Kraft AS, Kang Y: Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. J Hematol Oncol 2013, 29:6-12.
• [32]Fox CJ, Hammerman PS, Thompson CB: The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 2005, 201:259-266.
• [33]Wang Z, Bhattacharya N, Weaver M, Petersen K, Meyer M, Gapter L, Magnuson NS: Pim-1: A serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2001, 2:167-179.
• [34]Cuypers HT, Selten G, Berns A, van Kessel AH G: Assignment of the human homologue of Pim-1, a mouse gene implicated in leukemogenesis, to the pter-q12 region of chromosome 6. Hum Genet 1986, 72:262-265.
• [35]Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ: Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004, 571:43-49.
• [36]Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, Arthur JS: Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol 2006, 7:1.
• [37]Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M: The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003, 278:45358-45367.
• [38]Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N: Pim-3, a proto-oncogene with serine/ threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 2006, 66:6741-6747.
• [39]Gu JJ, Wang Z, Reeves R, Magnuson NS: PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis. Oncogene 2009, 28:4261-4271.
• [40]Hogan C, Hutchison C, Marcar L, Milne D, Saville M, Goodlad J, Kernohan N, Meek D: Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma. J Biol Chem 2008, 283:18012-18023.
• [41]Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001, 3:973-982.
• [42]Mayo LD, Donner DB: A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 2001, 98:11598-11603.
• [43]Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber HO, MacRae EJ, Vousden KH: Phosphorylation of HDM2 by Akt. Oncogene 2002, 21:1955-1962.
• [44]Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M: Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 2002, 21:1299-1303.
• [45]Jackson MW, Patt LE, LaRusch GA, Donner DB, Stark GR, Mayo LD: Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells. J Biol Chem 2006, 281:16814-16820.
• [46]Weber HO, Ludwig RL, Morrison D, Kotlyarov A, Gaestel M, Vousden KH: HDM2 phosphorylation by MAPKAP kinase 2. Oncogene 2005, 24:1965-1972.
• [47]Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G: The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998, 17:5001-5014.
• [48]Llanos S, Clark PA, Rowe J, Peters G: Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 2001, 3:445-452.
• [49]Hammerman PS, Fox CJ, Cinalli RM, Xu A, Wagner JD, Lindsten T, Thompson CB: Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation. Cancer Res 2004, 64:8341-8348.
• [50]Nihira K, Ando Y, Yamaguchi T, Kagami Y, Miki Y, Yoshida K: Pim-1 controls NF-kappaB signalling by stabilizing RelA/p65. Cell Death Differ 2010, 17:689-698.
• [51]Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS: Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002, 1593:45-55.
• [52]Wang Z, Zhang Y, Gu JJ, Davitt C, Reeves R, Magnuson NS: Pim-2 phosphorylation of p21(Cip1/WAF1) enhances its stability and inhibits cell proliferation in HCT116 cells. Int J Biochem Cell Biol 2010, 42:1030-1038.
• [53]Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N: Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 2008, 68:5076-5085.
• [54]Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, Zhou BP, Hung MC: Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 2004, 10:3815-3824.
• [55]Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001, 3:245-252.
• [56]Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus DB, Jain A: Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther 2009, 8:2882-2893.
• [57]Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y: Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 1999, 274:18659-18666.
• [58]Bachmann M, Hennemann H, Xing PX, Hoffmann I, Moroy T: The oncogenic ser- ine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 2004, 279:48319-48328.
• [59]Bhattacharya N, Wang Z, Davitt C, McKenzie IF, Xing PX, Magnuson NS: Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 2002, 111:80-95.
• [60]Yip-Schneider MT, Horie M, Broxmeyer HE: Transcriptional induction of pim-1 protein kinase gene expression by interferon gamma and posttranscriptional effects on costimulation with steel factor. Blood 1995, 85:3494-3502.
• [61]Chen XP, Losman JA, Cowan S, Donahue E, Fay S, Vuong BQ, Nawijn MC, Capece D, Cohan VL, Rothman P: Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci U S A 2002, 99:2175-2180.
• [62]Peltola KJ, Paukku K, Aho TL, Ruuska M, Silvennoinen O, Koskinen PJ: Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 2004, 103:3744-3750.
• [63]Chen JL, Limnander A, Rothman PB: Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 2008, 111:1677-1685.
• [64]Berns A, Mikkers H, Krimpenfort P, Allen J, Scheijen B, Jonkers J: Identification and characterization of collaborating oncogenes in compound mutant mice. Cancer Res 1999, 59(Suppl):1773-1777.
• [65]Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T: Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999, 11:709-719.
• [66]Zhang Y, Wang Z, Li X, Magnuson NS: Pim kinase‐dependent inhibition of c‐Myc degradation. Oncogene 2008, 27:4809-4819.
• [67]Zippo A, De Robertis A, Serafini R, Oliviero S: PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 2007, 9:932-944.
• [68]Winter S, Simboeck E, Fischle W, Zupkovitz G, Dohnal I, Mechtler K, Ammerer G, Seiser C: 14‐3‐3 proteins recognize a histone code at histone H3 and are required for transcriptional activation. EMBO J 2008, 27:88-99.
• [69]Zippo A, Serafini R, Rocchigiani M, Pennacchini S, Krepelova A, Oliviero S: Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. Cell 2009, 138:1122-1136.
• [70]Nakayama KI, Nakayama K: Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006, 6:369-381.
• [71]Matsumoto A, Onoyama I, Nakayama KI: Expression of mouse Fbxw7 isoforms is regulated in a cell cycle- or p53-dependent manner. Biochem Biophys Res Commun 2006, 350:114-119.
• [72]Yoshida GJ, Saya H: Inversed relationship between CD44 variant and c-Myc due to oxidative stress-induced canonical Wnt activation. Biochem Biophys Res Commun 2014, 443:622-627.
• [73]Reavie L, Della Gatta G, Crusio K, Aranda-Orgilles B, Buckley SM, Thompson B, Lee E, Gao J, Bredemeyer AL, Helmink BA, Zavadil J, Sleckman BP, Palomero T, Ferrando A, Aifantis I: Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. Nat Immunol 2010, 11:207-215.
• [74]Reavie L, Buckley SM, Loizou E, Takeishi S, Aranda-Orgilles B, Ndiaye-Lobry D, Abdel-Wahab O, Ibrahim S, Nakayama KI, Aifantis I: Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell 2013, 23:362-375.
• [75]Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, Graham CA, Hariharan IK, Harkin DP, Haber DA, Bell DW: Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol Oncol 2005, 98:124-128.
• [76]Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI: Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001, 413:316-322.
• [77]Spruck CH, Strohmaier H, Sangfelt O, Muller HM, Hubalek M, Muller-Holzner E, Marth C, Widschwendter M, Reed SI: hCDC4 gene mutations in endometrial cancer. Cancer Res 2002, 62:4535-4539.
• [78]Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C: Inactivation of hCDC4 can cause chromosomal instability. Nature 2004, 428:77-81.
• [79]Siu KT, Xu Y, Swartz KL, Bhattacharyya M, Gurbuxani S, Hua Y, Minella AC: Chromosome instability underlies hematopoietic stem cell dysfunction and lymphoid neoplasia associated with impaired Fbw7- mediated cyclin E regulation. Mol Cell Biol 2014, 34:3244-3258.
• [80]Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008, 40:43-50.
• [81]Liu L, Wang S, Chen R, Wu Y, Zhang B, Huang S, Zhang J, Xiao F, Wang M, Liang Y: Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. Biochem Biophys Res Commun 2012, 425:368-373.
• [82]Hammerman PS, Fox CJ, Brinbaum MJ, Thompson CB: Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 2005, 105:4477-4483.
• [83]Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J, Shi W, Zhang Z, Rajasekhar VK, Pagano NC, Porco JA Jr, Teruya-Feldstein J, Rosen N, Zelenetz AD, Pelletier J, Wendel HG: Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med 2011, 208:1799-1807.
• [84]Cen B, Xiong Y, Song JH, Mahajan S, DuPont R, McEachern K, DeAngelo DJ, Cortes JE, Minden MD, Ebens A, Mims A, LaRue AC, Kraft AS: The Pim-1 Protein Kinase Is an Important Regulator of MET Receptor Tyrosine Kinase Levels and Signaling. Mol Cell Biol 2014, 34:2517-2532.
• [85]Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf D, Zhang J, Ratajczak J, Ratajczak M: CXCR4–SDF-1 signaling, locomotion, chemotaxis and adhesion. J Mol Histol 2004, 35:233-245.
• [86]Lapidot T, Dar A, Kollet O: How do stem cells find their way home? Blood 2005, 106:1901-1910.
• [87]Busillo JM, Benovic JL: Regulation of CXCR4 signaling. Biochim Biophys Acta 2007, 1768:952-963.
• [88]Boudot A, Kerdivel G, Lecomte S, Flouriot G, Desille M, Godey F, Leveque J, Tas P, Le Dréan Y, Pakdel F: COUP-TFI modifies CXCL12 and CXCR4 expression by activating EGF signaling and stimulates breast cancer cell migration. BMC Cancer 2014, 14:407.
• [89]Matteucci E, Locati M, Desiderio MA: Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness. Exp Cell Res 2005, 310:176-185.
• [90]Chetram MA, Don-Salu-Hewage AS, Hinton CV: ROS enhances CXCR4-mediated functions through inactivation of PTEN in prostate cancer cells. Biochem Biophys Res Commun 2011, 410:195-200.
• [91]Matsusaka S, Tohyama Y, He J, Shi Y, Hazama R, Kadono T, Kurihara R, Tohyama K, Yamamura H: Protein-tyrosine kinase, Syk, is required for CXCL12-induced polarization of B cells. Biochem Biophys Res Commun 2005, 328:1163-1169.
• [92]Croker AK, Allan AL: Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 2008, 12:374-390.
• [93]Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S, Pogacic V, Villa A, Ehret S, Berridge G, Spoo A, Dierks C, Biondi A, Knapp S, Duyster J, Schwaller J: Dissection of PIM serine/threonine kinases in FLT3-ITD- induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med 2009, 206:1957-1970.
• [94]Decker S, Finter J, Forde AJ, Kissel S, Schwaller J, Mack TS, Kuhn A, Gray N, Follo M, Jumaa H, Burger M, Zirlik K, Pfeifer D, Miduturu CV, Eibel H, Veelken H, Dierks C: PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1). Mol Cancer Ther 2014, 13:1231-1245.
• [95]Chen W, Kumar AR, Hudson WA, Li Q, Wu B, Staggs RA, Lund EA, Sam TN, Kersey JH: Gene dosage and critical target cells. Cancer Cell 2008, 13:432-440.
• [96]Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Böhmer FD, Müller-Tidow C, Berdel WE, Serve H: Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003, 101:3164-3173.
• [97]Hu YL, Passegue E, Fong S, Largman C, Lawrence HJ: Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood 2007, 109:4732-4738.
• [98]Vu HA, Xinh PT, Kano Y, Tokunaga K, Sato Y: The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation. Biochem Biophys Res Commun 2009, 383:308-313.
• [99]Gomez-Abad C, Pisonero H, Blanco-Aparicio C, Roncador G, González-Menchén A, Martinez-Climent JA, Mata E, Rodríguez ME, Muñoz-González G, Sánchez-Beato M, Leal JF, Bischoff JR, Piris MA: PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood 2011, 118:5517-5527.
• [100]Brault L, Menter T, Obermann EC, Knapp S, Thommen S, Schwaller J, Tzankov A: PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. Br J Cancer 2012, 107:491-500.
• [101]Hsi ED, Jung SH, Lai R, Johnson JL, Cook JR, Jones D, Devos S, Cheson BD, Damon LE, Said J: Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 2008, 49:2081-2090.
• [102]Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Küppers R, Dalla-Favera R: Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001, 412:341-346.
• [103]Claudio JO, Masih-Khan E, Tang H, Gonçalves J, Voralia M, Li ZH, Nadeem V, Cukerman E, Francisco-Pabalan O, Liew CC, Woodgett JR, Stewart AK: A molecular compendium of genes expressed in multiple myeloma. Blood 2002, 100:2175-2186.
• [104]Pogacic V, Bullock AN, Fedorov O, Filippakopoulos P, Gasser C, Biondi A, Meyer-Monard S, Knapp S, Schwaller J: Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 2007, 67:6916-6924.
• [105]Blanco-Aparicio C, Collazo AM, Oyarzabal J, Leal JF, Albarán MI, Lima FR, Pequeño B, Ajenjo N, Becerra M, Alfonso P, Reymundo MI, Palacios I, Mateos G, Quiñones H, Corrionero A, Carnero A, Pevarello P, Lopez AR, Fominaya J, Pastor J, Bischoff JR: Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Lett 2011, 300:145-153.
• [106]Garcia PD, Langowski JL, Wang Y, Chen M, Castillo J, Fanton C, Ison M, Zavorotinskaya T, Dai Y, Lu J, Niu XH, Basham S, Chan J, Yu J, Doyle M, Feucht P, Warne R, Narberes J, Tsang T, Fritsch C, Kauffmann A, Pfister E, Drueckes P, Trappe J, Wilson C, Han W, Lan J, Nishiguchi G, Lindvall M, Bellamacina C, Aycinena JA, Zang R, Holash J, Burger MT: Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res 2014, 20:1834-1845.
• [107]Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V: Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009, 114:4150-4157.
• [108]Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V: Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 2011, 118:693-702.
• [109]Yang Q, Chen LS, Neelapu SS, Miranda RN, Medeiros LJ, Gandhi V: Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood 2012, 120:3491-3500.
• [110]Hospital MA, Green AS, Lacombe C, Mayeux P, Bouscary D, Tamburini J: The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells. Blood 2012, 119:1791-1792.
• [111]Fischer KM, Cottage CT, Konstandin MH, Völkers M, Khan M, Sussman MA: Pim-1 kinase inhibits pathological injury by promoting cardioprotective signaling. J Mol Cell Cardiol 2011, 51:554-558.
• [112]Quijada P, Toko H, Fischer KM, Bailey B, Reilly P, Hunt KD, Gude NA, Avitabile D, Sussman MA: Preservation of myocardial structure is enhanced by pim-1 engineering of bone marrow cells. Circ Res 2012, 111:77-86.
• [113]Lin YW, Beharry ZM, Hill EG, Song JH, Wang W, Xia Z, Zhang Z, Aplan PD, Aster JC, Smith CD, Kraft AS: A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 2010, 115:824-833.
• [114]Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z, Lilly M, Smith CD, Kraft AS: Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther 2009, 8:1473-1483.
• [115]Dakin LA, Block MH, Chen H, Code E, Dowling JE, Feng X, Ferguson AD, Green I, Hird AW, Howard T, Keeton EK, Lamb ML, Lyne PD, Pollard H, Read J, Wu AJ, Zhang T, Zheng X: Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett 2012, 22:4599-4604.
• [116]Meja K, Stengel C, Sellar R, Huszar D, Davies BR, Gale RE, Linch DC, Khwaja A: PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. Br J Haematol 2014, 167:69-79.
• [117]Brzózka K, Windak R, Guratowska M, Krawczyńska K, Kłosowska-Wardęga A, Zurawska M, Trębacz E, Sabiniarz A, Czardybon W, Chołody M, Horvath R, Szamborska-Gbur A, Prymula K, Milik M, Kowalczyk P, Rzymski T, Beuzen N: Preclinical development of a Pim kinase inhibitor for cancer treatment. [abstract]. Cancer Res 2012, 72:s1.
• [118]Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, Kaur S, Wang S, Chen Y, Wu A, Shen M, Gibbons FD, Lamb ML, Zheng X, Stone RM, Deangelo DJ, Platanias LC, Dakin LA, Chen H, Lyne PD, Huszar D: AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 2014, 123:905-913.
• [119]Fathi AT, Arowojolu O, Swinnen I, Sato T, Rajkhowa T, Small D, Marmsater F, Robinson JE, Gross SD, Martinson M, Allen S, Kallan NC, Levis M: A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Leuk Res 2012, 36:224-231.